Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Gossamer Bio Securities Class Action
Business securities lawsuit

Gossamer Bio Securities Class Action

Analysis based on 7 articles · First reported May 01, 2026 · Last updated May 16, 2026

Sentiment
-70
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The adverse results of Gossamer Bio's Phase 3 PROSERA study caused its stock price to plummet by over 80%, leading to a securities class action lawsuit. This event highlights the significant risks associated with clinical trials in the biotechnology industry and can lead to increased scrutiny of pharmaceutical companies' disclosures.

Biotechnology Legal Services
Event Summary

Gossamer Bio is facing a federal securities class action lawsuit initiated by Faruqi & Faruqi. The lawsuit alleges that Gossamer Bio and its executives made false and/or misleading statements and failed to disclose issues with the study design for its Phase 3 PROSERA study, specifically regarding the placebo response at Latin American testing sites. On February 23, 2026, Gossamer Bio announced that the PROSERA study failed to meet its primary endpoint, causing its common stock price to drop by more than 80% in a single trading day. Faruqi & Faruqi is encouraging investors who suffered losses to contact them to discuss their legal rights and the deadline to seek the role of lead plaintiff in the class action.

Key Actions
100 Gossamer Bio made false statements
90 Faruqi & Faruqi investigating claims Gossamer Bio
70 Gossamer Bio attributed outcome
Entities Involved
stock
Gossamer Bio
Gossamer Bio is facing a securities class action lawsuit due to alleged misleading statements regarding its Phase 3 PROSERA study, which led to an over 80% drop in its stock price.
Importance 100 Sentiment -90
priv
Faruqi & Faruqi
Faruqi & Faruqi is a national securities law firm investigating potential claims against Gossamer Bio and reminding investors of the deadline to seek lead plaintiff status in the class action lawsuit.
Importance 80 Sentiment 50
per
James Wilson
James Wilson, a partner at Faruqi & Faruqi, is encouraging investors who suffered losses in Gossamer Bio to contact him.
Importance 20 Sentiment 30
index
Nasdaq-100
Gossamer Bio's stock is traded on Nasdaq-100, and its price plummeted following the adverse study results.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.